NCT03959540View on ClinicalTrials.gov

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

CompletedOBSERVATIONAL
Enrollment

39

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

May 11, 2021

Study Completion Date

May 11, 2021

Conditions
Parkinson Disease
Interventions
DRUG

Opicapone

Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.

DRUG

Levodopa (L-DOPA) + Standard care

Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.

Trial Locations (1)

NR47UY

Norfolk&Norwich University Hospitals, Norwich

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT03959540 - Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter